Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.11
LH's Cash to Debt is ranked lower than
92% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. LH: 0.11 )
Ranked among companies with meaningful Cash to Debt only.
LH' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.11 Max: 0.29
Current: 0.11
0.02
0.29
Equity to Asset 0.36
LH's Equity to Asset is ranked lower than
78% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LH: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
LH' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.41 Max: 0.63
Current: 0.36
0.14
0.63
Interest Coverage 5.22
LH's Interest Coverage is ranked lower than
78% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.72 vs. LH: 5.22 )
Ranked among companies with meaningful Interest Coverage only.
LH' s Interest Coverage Range Over the Past 10 Years
Min: 3.65  Med: 11.28 Max: 14.88
Current: 5.22
3.65
14.88
F-Score: 4
Z-Score: 2.16
M-Score: -2.15
WACC vs ROIC
6.79%
6.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.68
LH's Operating margin (%) is ranked higher than
81% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. LH: 12.68 )
Ranked among companies with meaningful Operating margin (%) only.
LH' s Operating margin (%) Range Over the Past 10 Years
Min: 11.55  Med: 18.38 Max: 19.94
Current: 12.68
11.55
19.94
Net-margin (%) 6.44
LH's Net-margin (%) is ranked higher than
73% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. LH: 6.44 )
Ranked among companies with meaningful Net-margin (%) only.
LH' s Net-margin (%) Range Over the Past 10 Years
Min: 5.03  Med: 10.30 Max: 12.02
Current: 6.44
5.03
12.02
ROE (%) 12.25
LH's ROE (%) is ranked higher than
79% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.45 vs. LH: 12.25 )
Ranked among companies with meaningful ROE (%) only.
LH' s ROE (%) Range Over the Past 10 Years
Min: 11.25  Med: 22.35 Max: 28.64
Current: 12.25
11.25
28.64
ROA (%) 4.16
LH's ROA (%) is ranked higher than
70% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. LH: 4.16 )
Ranked among companies with meaningful ROA (%) only.
LH' s ROA (%) Range Over the Past 10 Years
Min: 4.06  Med: 9.59 Max: 11.43
Current: 4.16
4.06
11.43
ROC (Joel Greenblatt) (%) 46.47
LH's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. LH: 46.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 54.62  Med: 110.13 Max: 138.05
Current: 46.47
54.62
138.05
Revenue Growth (3Y)(%) 14.00
LH's Revenue Growth (3Y)(%) is ranked higher than
79% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. LH: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.4  Med: 10.20 Max: 19.9
Current: 14
-21.4
19.9
EBITDA Growth (3Y)(%) 3.80
LH's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. LH: 3.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.3  Med: 10.20 Max: 17.6
Current: 3.8
-8.3
17.6
EPS Growth (3Y)(%) -10.10
LH's EPS Growth (3Y)(%) is ranked lower than
66% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.60 vs. LH: -10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.1  Med: 15.30 Max: 82.8
Current: -10.1
-10.1
82.8
» LH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

LH Guru Trades in Q1 2015

John Hussman 90,000 sh (New)
Caxton Associates 3,000 sh (New)
John Keeley 10,760 sh (New)
Ray Dalio 96,536 sh (+37.84%)
Mario Gabelli 5,000 sh (+25.00%)
John Rogers 1,404,802 sh (+1.31%)
First Pacific Advisors 50,400 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Charles Brandes Sold Out
Scott Black 73,891 sh (-0.22%)
Jeff Auxier 4,180 sh (-8.73%)
Richard Pzena 728,078 sh (-12.35%)
Paul Tudor Jones 10,793 sh (-21.25%)
Chris Davis 4,443,459 sh (-25.05%)
Wallace Weitz 746,258 sh (-25.12%)
Jeremy Grantham 39,680 sh (-56.48%)
Jim Simons 250,605 sh (-58.03%)
Joel Greenblatt 104,024 sh (-63.43%)
» More
Q2 2015

LH Guru Trades in Q2 2015

David Dreman 5,976 sh (New)
Louis Moore Bacon 10,027 sh (New)
Larry Robbins 3,983,595 sh (New)
John Keeley 20,600 sh (+91.45%)
Jeremy Grantham 66,780 sh (+68.30%)
Mario Gabelli 6,000 sh (+20.00%)
Scott Black 80,011 sh (+8.28%)
John Rogers 1,501,141 sh (+6.86%)
Jeff Auxier 4,305 sh (+2.99%)
John Hussman 90,000 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
Caxton Associates Sold Out
Richard Pzena 719,376 sh (-1.20%)
Wallace Weitz 720,849 sh (-3.40%)
Chris Davis 4,215,809 sh (-5.12%)
Joel Greenblatt 80,999 sh (-22.13%)
Jim Simons 191,605 sh (-23.54%)
Paul Tudor Jones 6,200 sh (-42.56%)
Ray Dalio 39,991 sh (-58.57%)
» More
Q3 2015

LH Guru Trades in Q3 2015

Pioneer Investments 7,744 sh (New)
Andreas Halvorsen 5,053,349 sh (New)
Ray Dalio 56,011 sh (+40.06%)
Larry Robbins 4,865,795 sh (+22.15%)
John Rogers 1,627,421 sh (+8.41%)
Wallace Weitz 735,729 sh (+2.06%)
John Hussman 90,000 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Jeff Auxier 4,180 sh (-2.90%)
Mario Gabelli 5,600 sh (-6.67%)
Scott Black 73,916 sh (-7.62%)
John Keeley 18,925 sh (-8.13%)
Jeremy Grantham 50,190 sh (-24.84%)
Chris Davis 2,036,449 sh (-51.69%)
Joel Greenblatt 33,765 sh (-58.31%)
Richard Pzena 273,766 sh (-61.94%)
Jim Simons 68,405 sh (-64.30%)
David Dreman 486 sh (-91.87%)
» More
Q4 2015

LH Guru Trades in Q4 2015

Jana Partners 696,034 sh (New)
John Paulson 23,600 sh (New)
Paul Tudor Jones 175,000 sh (New)
John Keeley 79,150 sh (+318.23%)
Pioneer Investments 26,829 sh (+246.45%)
Jim Simons 117,505 sh (+71.78%)
Larry Robbins 5,657,018 sh (+16.26%)
John Rogers 1,675,352 sh (+2.95%)
Mario Gabelli 5,600 sh (unchged)
David Dreman 486 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
John Hussman Sold Out
Joel Greenblatt Sold Out
Wallace Weitz 700,037 sh (-4.85%)
Chris Davis 1,778,955 sh (-12.64%)
Jeff Auxier 3,330 sh (-20.33%)
Andreas Halvorsen 3,208,708 sh (-36.50%)
Ray Dalio 18,026 sh (-67.82%)
Jeremy Grantham 14,700 sh (-70.71%)
Scott Black 19,511 sh (-73.60%)
Richard Pzena 17,560 sh (-93.59%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Laboratory Corp of America Holdings

Weitz Funds Comments on Laboratory Corp. of America Holdings - Apr 25, 2016

Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corporation of America Holdings - Feb 01, 2016

Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations.



From Weitz Funds' Balanced Fund fourth quarter 2015 commentary.



Check out Wallace Weitz latest stock trades

John Rogers Comments on Laboratory Corp. of America Holdings - May 07, 2014

We purchased a previous holding in our mid ca p fund, Laboratory Corp. of America Holdings (LH). LabCorp maintains a leading market position in an indust ry that continues to show promising growth potential du e to technological advances, aging demographics, health care cost containment, and preventative medicine. LabCorp maintains a solid balance sheet, generates a significant amount of free cash flow and has been returning value to shareholders through share repurchases. The company operates with an experienced management team that is conservative yet willing to take slight risks in order to grow the business long-term.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Laboratory Corp of America Holdings

Weitz Funds Comments on Laboratory Corp. of America Holdings Guru stock highlight
Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come. Read more...
Weitz Funds Comments on Laboratory Corporation of America Holdings Guru stock highlight
Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations. Read more...
Halvorsen's Investment Makes Broadcom His 5th-Most Valuable Stake Health care-oriented guru acquires stake in Netflix in 3rd quarter
Health care stocks have the highest weighting – 30% – in Andreas Halvorsen (Trades, Portfolio)’s portfolio so it shouldn’t be a surprise that many of his largest transactions in the third quarter involved health care-related stocks, but his largest deal of the quarter belongs more properly to the second-highest weighted sector in his portfolio, Technology. Read more...
Andreas Halvorsen Buys Stake in Laboratory Corp. of America Holdings Guru acquires more than 5 million shares of health care network operator
Andreas Halvorsen (Trades, Portfolio) of Viking Global Investors LP bought a stake in Laboratory Corp. of America Hldgs. (NYSE:LH) on Oct. 1. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.44
LH's P/E(ttm) is ranked higher than
68% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.31 vs. LH: 21.44 )
Ranked among companies with meaningful P/E(ttm) only.
LH' s P/E(ttm) Range Over the Past 10 Years
Min: 12.98  Med: 17.21 Max: 29.51
Current: 21.44
12.98
29.51
Forward P/E 13.02
LH's Forward P/E is ranked higher than
90% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.92 vs. LH: 13.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.48
LH's PE(NRI) is ranked higher than
68% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.12 vs. LH: 21.48 )
Ranked among companies with meaningful PE(NRI) only.
LH' s PE(NRI) Range Over the Past 10 Years
Min: 12.97  Med: 17.22 Max: 29.56
Current: 21.48
12.97
29.56
Price/Owner Earnings (ttm) 16.69
LH's Price/Owner Earnings (ttm) is ranked higher than
74% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.08 vs. LH: 16.69 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LH' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.24  Med: 13.70 Max: 34.91
Current: 16.69
9.24
34.91
P/B 2.45
LH's P/B is ranked higher than
62% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. LH: 2.45 )
Ranked among companies with meaningful P/B only.
LH' s P/B Range Over the Past 10 Years
Min: 2.11  Med: 3.50 Max: 5.19
Current: 2.45
2.11
5.19
P/S 1.44
LH's P/S is ranked higher than
76% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. LH: 1.44 )
Ranked among companies with meaningful P/S only.
LH' s P/S Range Over the Past 10 Years
Min: 1.19  Med: 1.67 Max: 3
Current: 1.44
1.19
3
PFCF 17.65
LH's PFCF is ranked higher than
72% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.30 vs. LH: 17.65 )
Ranked among companies with meaningful PFCF only.
LH' s PFCF Range Over the Past 10 Years
Min: 9.24  Med: 15.04 Max: 32.44
Current: 17.65
9.24
32.44
POCF 12.97
LH's POCF is ranked higher than
68% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.11 vs. LH: 12.97 )
Ranked among companies with meaningful POCF only.
LH' s POCF Range Over the Past 10 Years
Min: 7.53  Med: 11.52 Max: 21.26
Current: 12.97
7.53
21.26
EV-to-EBIT 18.22
LH's EV-to-EBIT is ranked higher than
53% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. LH: 18.22 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 11.70 Max: 21.5
Current: 18.22
8.7
21.5
EV-to-EBITDA 12.55
LH's EV-to-EBITDA is ranked higher than
57% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.76 vs. LH: 12.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
LH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 9.60 Max: 16.1
Current: 12.55
7.2
16.1
PEG 5.58
LH's PEG is ranked lower than
87% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. LH: 5.58 )
Ranked among companies with meaningful PEG only.
LH' s PEG Range Over the Past 10 Years
Min: 0.86  Med: 1.52 Max: 6.25
Current: 5.58
0.86
6.25
Shiller P/E 23.77
LH's Shiller P/E is ranked higher than
80% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.90 vs. LH: 23.77 )
Ranked among companies with meaningful Shiller P/E only.
LH' s Shiller P/E Range Over the Past 10 Years
Min: 18.8  Med: 23.66 Max: 75.2
Current: 23.77
18.8
75.2
Current Ratio 1.57
LH's Current Ratio is ranked lower than
73% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. LH: 1.57 )
Ranked among companies with meaningful Current Ratio only.
LH' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.69 Max: 3.1
Current: 1.57
0.79
3.1
Quick Ratio 1.45
LH's Quick Ratio is ranked lower than
70% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. LH: 1.45 )
Ranked among companies with meaningful Quick Ratio only.
LH' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.57 Max: 2.91
Current: 1.45
0.72
2.91
Days Inventory 10.94
LH's Days Inventory is ranked higher than
92% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. LH: 10.94 )
Ranked among companies with meaningful Days Inventory only.
LH' s Days Inventory Range Over the Past 10 Years
Min: 10.44  Med: 12.26 Max: 13.25
Current: 10.94
10.44
13.25
Days Sales Outstanding 52.39
LH's Days Sales Outstanding is ranked higher than
62% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. LH: 52.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.64  Med: 49.42 Max: 55.91
Current: 52.39
44.64
55.91
Days Payable 27.44
LH's Days Payable is ranked lower than
79% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. LH: 27.44 )
Ranked among companies with meaningful Days Payable only.
LH' s Days Payable Range Over the Past 10 Years
Min: 20.61  Med: 26.17 Max: 32.38
Current: 27.44
20.61
32.38

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.99
LH's Price/Projected FCF is ranked higher than
89% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. LH: 0.99 )
Ranked among companies with meaningful Price/Projected FCF only.
LH' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.74  Med: 1.02 Max: 6.11
Current: 0.99
0.74
6.11
Price/DCF (Earnings Based) 1.82
LH's Price/DCF (Earnings Based) is ranked higher than
57% of the 14 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. LH: 1.82 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.86
LH's Price/Median PS Value is ranked higher than
62% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. LH: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
LH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.96 Max: 1.64
Current: 0.86
0.07
1.64
Earnings Yield (Greenblatt) (%) 5.45
LH's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. LH: 5.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 8.60 Max: 11.4
Current: 5.45
4.7
11.4
Forward Rate of Return (Yacktman) (%) 10.17
LH's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.85 vs. LH: 10.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LH' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 9.9  Med: 18.70 Max: 22.6
Current: 10.17
9.9
22.6

More Statistics

Revenue(Mil) $9255
EPS $ 5.79
Beta0.82
Short Percentage of Float3.35%
52-Week Range $97.79 - 128.84
Shares Outstanding(Mil)101.70

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 9,328 9,729 10,184
EPS($) 8.76 9.54 10.68
EPS without NRI($) 8.76 9.54 10.68

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:TMO, NYSE:A, TSE:6869, NYSE:DGX, XSWX:LONN » details
Traded in other countries:LAB.Germany,
Laboratory Corp of America Hldgs, founded in 1971, is an independent clinical laboratory company in the United States. Since the Company's founding, it has grown into a national network of 39 primary laboratories and over 1,750 patient service centers along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately). Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. The Company believes that it competes favorably with its principal competitors in each of these areas and is currently implementing strategies designed to improve its competitive position. The Company's strategic plan continues to focus on three critical priorities: scientific differentiation, managed care, and customer service. The Company offers its services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Primary Care, Obstetrics-Gynecology, Specialty Medicine (e.g., Infectious Disease, Endocrinology, Gastroenterology and Rheumatology), Oncology and Hospitals. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
» More Articles for LH

Headlines

Articles On GuruFocus.com
Weitz Funds Comments on Laboratory Corp. of America Holdings Apr 25 2016 
7 High Quality Guru Stocks Apr 11 2016 
Jana Partners Buys Pfizer, AIG, Microsoft Mar 16 2016 
John Hussman Sells Infosys, Cisco, Aetna Mar 15 2016 
Weitz Funds Comments on Laboratory Corporation of America Holdings Feb 01 2016 
Guru, Philanthropist Larry Robbins Adds to 3 Healthcare-Related Holdings Dec 06 2015 
Halvorsen's Investment Makes Broadcom His Fifth-Most Valuable Stake Dec 05 2015 
Andreas Halvorsen Buys Stake in Laboratory Corp. of America Holdings Oct 14 2015 
Eight Bridges Capital Management's July 2015 Investor Letter Sep 01 2015 
John Hussman's Top Five New Buys in the First Quarter May 12 2015 

More From Other Websites
ETF’s with exposure to Laboratory Corp. of America Holdings : May 2, 2016 May 02 2016
LabCorp Trades at Discounted PE Multiples Compared with Peers in 1Q16 May 02 2016
Lockheed Martin Corporation (LMT) and Two Other Companies Record Massive Insider Selling May 02 2016
LabCorp’s Growth Drivers in 1Q16: Organic Growth, Acquisitions Apr 30 2016
Covance Drug Development Drives LabCorp’s 1Q16 Revenue Growth Apr 29 2016
Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 29 2016
Rumors Of Deal Put INC Research In The Spotlight Apr 27 2016
Revenue Growth Initiatives Drove LabCorp’s Performance in 1Q16 Apr 27 2016
Must-Read Notes on LabCorp’s 1Q16 Earnings and Conference Call Apr 27 2016
The Best Stock In A Surefire Growth Industry Apr 26 2016
Company News for April 26, 2016 Apr 26 2016
Key Morning Earnings for April 25: FDC, LH, XRX Apr 25 2016
Why These Five Stocks Are in Spotlight Today? Apr 25 2016
LabCorp (LH) Tops Q1 Earnings and Sales, Raises Guidance Apr 25 2016
Laboratory Corporation of America Holdings Earnings Call scheduled for 9:00 am ET today Apr 25 2016
LabCorp (LH) Q1 Earnings in Line, Revenues Beat Estimates Apr 25 2016
Q1 2016 Laboratory Corporation of America Holdings Earnings Release - Before Market Open Apr 25 2016
Laboratory Corporation of America® Holdings Announces 2016 First Quarter Results and Raises 2016... Apr 25 2016
LabCorp beats Street 1Q forecasts Apr 25 2016
LabCorp beats Street 1Q forecasts Apr 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK